 |
|
|
| |
Hepatic Safety and Biomarker Assessments in Sorafenib-experienced Patients With Advanced Hepatocellular Carcinoma Treated With Nivolumab in the CheckMate-040 Study
|
| |
| |
Reported by Jules Levin
EASL 2018 April 11-15 Paris France
Tim Meyer,1Ignacio Melero,2,3Thomas Yau,4ChiunHsu,5Masatoshi Kudo,6Su-Pin Choo,7JörgTrojan,8Theodore H. Welling,9Yoon-Koo Kang,10Winnie
Yeo,11AkhilChopra,12AdybBaakili,13Christine delaCruz,13HuanyuZhao,13Jaclyn Neely,13Todd S. Crocenzi,14Anthony B. El-Khoueiry,15Bruno Sangro16
1Royal Free Hospital, London, UK; 2Clinica Universidad de Navarra and CIBERONC, Pamplona, Spain; 3Center for Applied Medical Research (CIMA), Pamplona, Spain;4University of Hong Kong, Hong Kong, China;5National Taiwan University Hospital, Taipei, Taiwan; 6Kindai University Faculty of Medicine, Osaka, Japan; 7National Cancer Centre, Singapore; 8Goethe University Hospital and Cancer Center, Frankfurt, Germany; 9New York University LangoneHealth, New York, NY, USA;10Asan Medical Center, University of Ulsan, Seoul, Korea; 11Chinese University of Hong Kong, Hong Kong, China;12OncoCare Cancer Centre, Singapore; 13Bristol-Myers Squibb, Princeton, NJ, USA; 14Providence Cancer Center, Portland, OR, USA; 15USC Norris Comprehensive Cancer Center, Los Angeles, CA, USA; 16Clinica Universidad de Navarra and CIBEREHD, Pamplona, Spain
|
| |
|
|
|
|
|
